| Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified studied in …STUDIED_INderived10 of 46show all (up to 200) |
|---|
| → studied in | NCT03862157Phase 1/Phase 2 · active not recruiting Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia · condition mapped ALIAS · 46 trials mapped (3 active) | — | — | Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03613532Phase 1 · active not recruiting Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN · condition mapped ALIAS · 46 trials mapped (3 active) | — | — | Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01384513Phase 2 · completed A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies · condition mapped ALIAS · 46 trials mapped (3 active) | — | — | Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01787487Phase 2 · completed Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm · condition mapped ALIAS · 46 trials mapped (3 active) | — | — | Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01199562active not recruiting Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant · condition mapped ALIAS · 46 trials mapped (3 active) | — | — | Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03878524Phase 1 · terminated Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial · condition mapped ALIAS · 46 trials mapped (3 active) | — | — | Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01894477Phase 2 · unknown Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia · condition mapped ALIAS · 46 trials mapped (3 active) | — | — | Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03807063Phase 1 · withdrawn Rivogenlecleucel Donor Lymphocyte Immunotherapy in Treating Patients With Recurrent Blood Cancers After Stem Cell Transplant · condition mapped ALIAS · 46 trials mapped (3 active) | — | — | Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00040846Phase 2 · completed Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies · condition mapped ALIAS · 46 trials mapped (3 active) | — | — | Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00006251Phase 1/Phase 2 · completed Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer · condition mapped ALIAS · 46 trials mapped (3 active) | — | — | Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified | 1 | Observed | clinicaltrials | graph → |